1[1]Minden M,Imrie K,Keating A.Acute leukemia in adults.Curr Opin Hematol,1996,3:259-265.
2[2]Silverman L B,Gelber R D,Young M L,et al.Induction failure in acute lymphoblastic leukemia of childhood.Cancer,1999,85: 1395-1404.
3[3]Cripe L D.Adult acute leukemia.Curr Probl Cancer,1997,21:1-64.
4[4]Michieli M,Damiani D,Ermacora A,et al.P-glycoprotein,lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias: Biological and clinical implications.Br J Haematol,1999,104:318-325.
5[5]Dorken B,Ludwig W D.Clinical significance of CD95,Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function,stage and cytogenetics.Leukemia,1999,13: 1943-1953.
6[6]Raanani P,Shpilberg O,Gillis S,et al.Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.Leuk Res,1999,23:695-700.
7[7]Pogliani E M,Belotti D,Rivolta G F,et al.Anthracycline drugs and MDR expression in human leukemia.Cytotechnology,1996,19: 229-235.
8[8]Bassan R,Lerede T,Rambaldi A,et al.Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia.Acta Haematol,1996,95: 188-192.
